Sodium chloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Sodium chloride
- Molecular weight
- 58.44
- Structure (SMILES)
These details could not be displayed.
- Aqsia (balanced salt soln)
- aqsia balanced salt soln
- askina
- Askina
- askina jet
- Askina jet
- balanced salt
- Balanced salt
- broncho saline
- Broncho saline
- Bss (balanced salt soln)
- bss balanced salt soln
- flowfusor
- Flowfusor
- fresenius
- Fresenius
- hypromellose in ringers soln
- Hypromellose in ringers soln
- Iocare (balanced salt soln)
- iocare balanced salt soln
- irriclens
- Irriclens
- isot saline
- Isot saline
- labmist
And 85 more, listed on the interactive page.
- %0.9 Saline
- 0 5 ml saline subcutaneous injection
- 0 9 nacl
- 0 9 saline
- 0 9 saline solution
- 0,9% saline
- 0,9% Saline
- 0.9 % saline
- 0.9% nacl
- 0.9% saline
- 0.9% Saline
- 0.9% saline solution
- 0.9%saline
- 1 ml saline infusion
- 5ml saline
- aqua marina
- AQUA MARINA
- AQUA MARINA [HPUS]
- aqua marina hpus
- b1655
- B1655
- B1655 [LANGUAL]
- b1655 langual
- Balanced salt solution (BSS)
- Balanced Salt Solution (BSS) Solution
And 143 more, listed on the interactive page.
- CAS registry numbers
- 7647-14-5
- ChEMBL ID
- CHEMBL1200574
- InChIKey
- FAPWRFPIFSIZLT-UHFFFAOYSA-M
- PubChem compound IDs
- 5234
- RxNorm IDs (RxCUI)
- 9863
- FDA ingredient codes (UNII)
- 451W47IQ8X
- A12CA01
- B05CB01
- B05XA03
- S01XA03
Sources for recorded values
- Applicant
- B BRAUN
- Approval date
- 12 Aug 1970
- Application number
- NDA016733
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
Administration routes
- Oral
- Parenteral
- topical
- Condition
- Acid-Base Imbalance
- Highest recorded phase
- 4
- Subject identifier
- D000137
- Condition
- Fluid Therapy
- Highest recorded phase
- 4
- Subject identifier
- D005440
- Condition
- HIV Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000180
- Subject identifier
- D015658
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Hodgkin Disease
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000183
- Subject identifier
- D006689
- Condition
- Myelodysplastic Syndromes
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000198
- Subject identifier
- D009190
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Dermatitis, Atopic
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0000274
- Subject identifier
- D003876
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Prostatic Hyperplasia
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000284
- Subject identifier
- D011470
- Condition
- Breast Neoplasms
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000305
- Subject identifier
- D001943
- Condition
- Carcinoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000313
- Subject identifier
- D002277
- Condition
- Cardiovascular Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000319
- Subject identifier
- D002318
- Condition
- Pulmonary Disease, Chronic Obstructive
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000341
- Subject identifier
- D029424
- Condition
- Pancreatitis, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000342
- Subject identifier
- D050500
- Condition
- Heart Failure
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000373
- Subject identifier
- D006333
- Condition
- Crohn Disease
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000384
- Subject identifier
- D003424
- Condition
- Melanoma
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000389
- Subject identifier
- D008545
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Cardiomyopathy, Dilated
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000407
- Subject identifier
- D002311
- Condition
- Carcinoma, Intraductal, Noninfiltrating
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000432
- Subject identifier
- D002285
- Condition
- Emphysema
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000464
- Subject identifier
- D004646
- Condition
- Epilepsy
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000474
- Subject identifier
- D004827
- Condition
- Glioblastoma
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000519
- Subject identifier
- D005909
- Condition
- Hypertension
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
And 423 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000222
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000274
- Condition identifier
- EFO_0000275
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000284
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000305
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000319
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000341
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000342
- Condition identifier
- EFO_0000373
- Condition identifier
- EFO_0000389
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000400
- Condition identifier
- EFO_0000407
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000432
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000474
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000519
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000545
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000546
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000556
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000556
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000588
- Highest recorded phase
- 2
- Condition identifier
- EFO_0000612
- Highest recorded phase
- 3
And 473 more, listed on the interactive page.
- Event
- abdominal distension
- Reports
- 416
- Reporting signal score
- 451.918
- Event
- anterior chamber cell
- Reports
- 64
- Reporting signal score
- 200.737
- Event
- anterior chamber fibrin
- Reports
- 44
- Reporting signal score
- 186.085
- Event
- bloody peritoneal effluent
- Reports
- 183
- Reporting signal score
- 882.344
- Event
- device interaction
- Reports
- 66
- Reporting signal score
- 284.263
- Event
- endophthalmitis
- Reports
- 179
- Reporting signal score
- 401.595
- Event
- fatigue
- Reports
- 93
- Reporting signal score
- 279.282
- Event
- fluid overload
- Reports
- 442
- Reporting signal score
- 1,136.22
- Event
- fungal peritonitis
- Reports
- 186
- Reporting signal score
- 841.159
- Event
- hypervolaemia
- Reports
- 141
- Reporting signal score
- 495.724
- Event
- hypopyon
- Reports
- 71
- Reporting signal score
- 214.719
- Event
- noninfectious peritonitis
- Reports
- 42
- Reporting signal score
- 175.192
- Event
- peritoneal cloudy effluent
- Reports
- 71
- Reporting signal score
- 334.169
- Event
- peritoneal dialysis complication
- Reports
- 401
- Reporting signal score
- 1,925.07
- Event
- peritoneal disorder
- Reports
- 54
- Reporting signal score
- 190.151
- Event
- peritonitis
- Reports
- 1,434
- Reporting signal score
- 5,302.55
- Event
- peritonitis bacterial
- Reports
- 1,266
- Reporting signal score
- 5,735.55
- Event
- toxic anterior segment syndrome
- Reports
- 394
- Reporting signal score
- 1,733.67
- Event
- ultrafiltration failure
- Reports
- 126
- Reporting signal score
- 605.369
- NCT00041392
- NCT00516178
- NCT00524901
- NCT01348971
- NCT01519245
- NCT01658410
- NCT01878669
- NCT03184155
- NCT05399576
- NCT00059332
- NCT00840671
- NCT01088230
- NCT01527240
- NCT01669408
- NCT02810392
- NCT02838589
- NCT03463551
- NCT03696121
- NCT04041167
- NCT05691244
- NCT05869565
- NCT00069082
- NCT00180687
- NCT00337597
- NCT00470600
And 1,280 more, listed on the interactive page.
- Dose
- Per 8 ounces
- Route
- Oral
- How often
- Every 10 minutes until 4 liters are consumed
- Do not add ingredients or flavors
- Keep refrigerated for 2-8°C
- Take with water
- Use within 48 hours
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- Yes
- Heavy atoms
- 2
- Molecular formula
- ClNa
- Monoisotopic mass
- 57.9586220
- Natural product
- No
- 0019-1188
- 0065-0795
- 0065-1795
- 0264-1800
- 0264-1945
- 0264-2201
- 0264-2202
- 0264-2203
- 0264-2205
- 0264-5802
- 0264-5804
- 0264-7388
- 0264-7389
- 0264-7608
- 0264-7610
- 0264-7612
- 0264-7614
- 0264-7616
- 0264-7622
- 0264-7623
- 0264-7634
- 0264-7635
- 0264-7636
- 0264-7638
- 0264-7645
And 315 more, listed on the interactive page.
- Recorded assays
- 267
- Active assays
- 4
Active assay types
- Other
Related records
Trials (764)
- : Pulpal Blood Flow With the Use of Intra-nasal Anesthetic
- "The Effect of Reduced Fluid Load After Cardiac Surgery"
- 0,9% NaCl Effect on Kidney Function and Glycocalyx in Patients Operated on for Primary Hiparthrosis
- 0.9% Saline Versus Balanced Solutions in Severe Diabetic Ketoacidosis
- 20% Albumin vs. Balanced Salt Solution as Resuscitation Fluid in Cirrhosis With Sepsis Induced Hypotension
- 21 Day Cumulative Skin Irritation of RUT058-60
- 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
- 7% Hypertonic Saline for Acute Bronchiolitis
- A 21-Day Topical Safety Study of Diltiazem Hydrochloride Using a Cumulative Irritant Patch Test Design
- A 2nd Generation E1/E2B/E3-Deleted Adenoviral COVID-19 Vaccine: The TCELL VACCINE TRIAL
- A Clinical Study Evaluating the Dermal Safety of Soluble Denosumab Microneedle Patches
- A Clinical Study of Alanyl-Glutamine for Reduction of Post-Myomectomy Adhesions
- A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants
- A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP
- A Comparative Study With Parenteral Oxycodone, Morphine and Dexamethasone in Postoperative Pain in Paediatric Patients
- A Double-Blinded, Randomized Placebo Controlled Pilot Study Comparing the Efficacy and Safety of IncobotulinumtoxinA Versus Saline Injections to the Cheek Region in Patients With Rosacea
- A Heterologous 3rd COVID-19 Vaccine of MVC-COV1901 to Evaluate Immunogenicity and Safety in Adults With ChAdOx1-nCov-19
- A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade
- A Phase I, Randomized, Modified Single-blind, Active-controlled (Infants Only), Four-stage, Step-down, Comparative, Multi-center Study
- A Phase I/II Double-Blind, Randomized, Controlled Study to Evaluate the Safety and Efficacy of RUT058-60
Approved for (6)
- Common cold
- Congestive heart failure
- Corneal edema
- Diabetes mellitus
- Eye disorder
- Heart failure
In development for (361)
- Abscess Phase 3
- Achalasia Phase 2
- Achondroplasia Phase 1
- Acne Phase 2
- Acromegaly Phase 2
- Acute cholecystitis Phase 3
- Acute coronary syndrome Phase 2
- Acute kidney injury Phase 3
- Acute kidney tubular necrosis Phase 1
- Acute liver failure Phase 2
- Acute lung injury Phase 3
- Acute myeloid leukemia Phase 2
- Acute myocardial infarction Phase 3
- Acute pancreatitis Phase 3
- Acute respiratory distress syndrome Phase 2
- Adiposis dolorosa Phase 2
- Adult acute respiratory distress syndrome Phase 2
- Age-related macular degeneration Phase 2
- AIDS Phase 1
- Alcohol dependence Phase 3
Other linked conditions (4)
- Acute bronchiolitis
- Endophthalmitis
- Gastroesophageal reflux disease
- Lipoma